A compilation of meropenem tissue distribution data.
Meropenem body fluid and tissue concentration data from both published studies and samples obtained during efficacy evaluation have been compiled and presented according to a consistent format to facilitate comparison. The concentration data have been compared with the mode MIC data available for the pathogens isolated during the clinical evaluation of meropenem. These data support the widespread and rapid penetration of meropenem into the interstitial fluid of those tissues not protected by a tight epithelial barrier. Furthermore, they suggest that the proposed dosages of meropenem 500 mg or 1 g tds would provide an adequate duration of cover at tissue sites for the treatment of a range of commonly occurring pathogens. A higher dosage of 40 mg/kg or 2 g in adults given tds would be recommended for meningitis based on the penetration of meropenem into CSF. Overall, the tissue and body fluid data presented confirm the expectation, based on the plasma concentrations and theoretical arguments, that meropenem is rapidly and readily distributed into the interstitial fluid, thereby producing concentrations in tissues likely to be clinically effective. This is consistent with the available clinical data on the therapeutic efficacy of meropenem.
Zeneca Pharmaceuticals, Mereside, Macclesfield, Cheshire, UK.
M
M
Hutchison
K L
KL
Faulkner
P J
PJ
Turner
S J
SJ
Haworth
W
W
Sheikh
H
H
Nadler
D H
DH
Pitkin
D015780:Carbapenems / Q000493:pharmacokinetics*; D004341:Drug Evaluation; D006801:Humans; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D013845:Thienamycins / Q000032:analysis / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem